Fusion Antibodies PLC (AIM:FAB) rose 5% as it signed an agreement with a US firm, which will co-market its artificial intelligence and machine learning platform AI/ML-Ab.
Each firm will be entitled to a fee for any new business introduced to the other.
Adrian Kinkaid, Fusion Antibodies' chief executive, said: "We are delighted to be able to announce the successful delivery of the AI/ML-Ab service utilizing our established production and evaluation capabilities and an option to include our proprietary mammalian display technology.”
Shares rose 0.38p to 7.13p.